CSIMarket Company Name, Ticker, Industry, else..
 
Passage Bio inc   (NASDAQ: PASG)
Other Ticker:  
 
 
Price: $0.3296 $-0.04 -10.678%
Day's High: $0.37 Week Perf: -8.93 %
Day's Low: $ 0.32 30 Day Perf: -26.64 %
Volume (M): 41 52 Wk High: $ 1.64
Volume (M$): $ 13 52 Wk Avg: $0.75
Open: $0.37 52 Wk Low: $0.30



 Market Capitalization (Millions $) 20
 Shares Outstanding (Millions) 61
 Employees 88
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -65
 Cash Flow (TTM) (Millions $) 16
 Capital Exp. (TTM) (Millions $) 0

Passage Bio Inc
Passage Bio Inc. is a genetic medicines company that specializes in developing transformative therapies for rare, monogenic central nervous system (CNS) disorders. The company utilizes its proprietary gene therapy platform to develop innovative treatments that target the underlying causes of these genetic disorders. By harnessing the power of genetic medicine, Passage Bio aims to provide long-lasting and potentially curative therapies that can significantly improve the lives of patients suffering from these rare diseases. The company's pipeline includes multiple product candidates at different stages of development, with a focus on conditions such as GM1 gangliosidosis, frontotemporal dementia, and Krabbe disease. Passage Bio is committed to advancing its pipeline and partnering with experts, researchers, and patient communities to accelerate the development and delivery of life-changing treatments for rare genetic disorders.


   Company Address: One Commerce Square Philadelphia 19103 PA
   Company Phone Number: 866-0311   Stock Exchange / Ticker: NASDAQ PASG


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ALEC        10.2% 
BLUE   -7.84%    
CRSP        11.64% 
EDIT        17.39% 
PLX        7.47% 
VYGR        5.78% 
• View Complete Report
   



Clinical Study

Passage Bio to Showcase Innovations at Chardans 8th Annual Genetic Medicines Conference

Published Mon, Sep 23 2024 11:00 AM UTC

Passage Bio Inc. (NASDAQ: PASG), a company dedicated to developing innovative genetic medicines, will be presenting at the upcoming Chardan 8th Annual Genetic Medicines Conference. This prestigious event gathers leaders in the field of genetic medicine, providing a platform for dialogue around cutting-edge research, therapeutic developments, and the future landscape of genet...
Clinical Study

Passage Bio Unveils Promising Interim Data in FTD-GRN Study Amid Financial Challenges

Published Mon, Sep 16 2024 11:00 AM UTC

Passage Bio, Inc., a clinical-stage genetic medicine company, is poised to present interim data from its upliFT-D study at the upcoming 14th International Conference on Frontotemporal Dementias (ISFTD2024). This study focuses on patients with frontotemporal dementia caused by GRN mutations (FTD-GRN), and initial results have generated optimism within the scientific community...
Financing Agreement

Passage Bio and GEMMA Biotherapeutics Unite to Revolutionize Pediatric Gene Therapy

Published Thu, Aug 1 2024 11:00 AM UTC

Passage Bio Partners with GEMMA Biotherapeutics to Advance Pediatric Gene Therapy Programs
Imagine a world where devastating genetic diseases that afflict children have effective treatments. Thanks to groundbreaking research and collaboration, that world might not be too far away. Passage Bio, a leading genetic medicines company, has recently made a significant move by o...
Clinical Study

FDA Greenlights Expansion of Passage Bios upliFT-D Trial for PBFT02 to Address Frontotemporal Dementia in Patients w...

Published Tue, Jul 16 2024 11:00 AM UTC

Passage Bio Receives FDA Endorsement to Broaden upliFT-D Trial for PBFT02 to Encompass FTD-C9orf72 PatientsPassage Bio, a genetic medicines company focused on developing transformative therapies for rare monogenic central nervous system (CNS) disorders, has recently secured positive feedback from the U.S. Food and Drug Administration (FDA) regarding the expansion of its upl...
Passage Bio Inc

Unveiling the Success: PASG's Impressive Financial Performance for Q1 20242.

Passage Bio: A Promising Future Ahead
Passage Bio, Inc. (NASDAQ: PASG) has recently reported its financial results for the first quarter ended March 31, 2024, and the numbers have left shareholders pleasantly surprised. Despite not anticipating any adjustments at the top-line, shareholders observed a significant improvement in the company's operating deficit during the same period. This suggests that Passage Bio has been operating more efficiently and effectively than ever before, setting the stage for a bullish outlook in the coming quarters.
The rising business of Passage Bio has been competing more efficiently in the neurodegenerative diseases market. In comparison to the same period in the previous year, the company's operating deficit decreased from $-35.883 million to $-18.05 million. This impressive reduction in losses showcases the company's commitment to managing its operations more effectively. Moreover, throughout the fiscal interval closing March 31, 2024, the management team successfully cut diminishing returns from $-35.883 million to $-16.711 million. Such remarkable improvements indicate that Passage Bio is on the right path to long-term success.









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com